OBJECTIVE： To investigate therapeutic efficacy and safety of levamlodipine and telmisartan combined with hydrochlorothiazide in the treatment of anti-dipper hypertension. METHODS： Totally 150 patients with anti-dipper hypertension were randomly divided into group A， B， C， with 50 cases in each group. Group A was given Telmisartan tablet 40 mg+Hydrochlorothiazide tablet 10 mg， once a day， in the morning. Group B was given Levamlodipine tablet 5 mg， once a day， in the night. Group C was given Telmisartan tablet （usage and dosage same as group A）+Hydrochlorothiazide tablet （usage and dosage same as group A）+Levamlodipine tablet （usage and dosage same as group B）. Treatment courses of 3 groups lasted for 8 weeks. The changes of electrolyte and 24 h ambulatory blood pressure were observed and compared among 3 groups before and after treatment. The incidence of adverse reactions was recorded. RESULTS： There was no statistical significance in the electrolyte indexes in 3 groups before and after treatment（P＞0.05）. Before treatment，there was no statistical significance in 24 h blood pressure among 3 groups（P＞0.05）. After treatment， the 24 h blood pressure of the patients in the 3 groups after treatment was lower than before treatment， and group C was lower than that of the group A and group B （P＜0.05）. After treatment， the rate of anti-dipper rhythm reversal in group C was significantly higher than group A and B， with statistical significance（P＜0.05）. There was no statistical significance in the incidence of ADR among 3 groups（P＞0.05）. CONCLUSIONS： Levamlodipine and telmisartan combined with hydrochlorothiazide show good therapeutic efficacy for anti-dipper hypertension， and can reduce 24 h blood pressure and effectively reverse anti-dipper rhythm with good safety.